Sectors
The oversubscribed series A round featured Zaffre Investments, the corporate venturing arm of insurance provider Blue Cross Blue Shield.
Kyee, the SoftBank-backed developer of a range of healthcare-focused management software, has now raised nearly $60m since it was founded.
The Celgene and Sorrento-backed immunotherapy drug developer initially raised $207m when it floated on Nasdaq last week.
Almirall invested $15m in dermatological products manufacturer Suneva as part of a larger debt and equity round.
Fosun and Walgreens-backed telehealth company TytoCare has added Cambia Health Solutions to its investor base and has now raised $18.5m in total.
Recently formed Mereo BioPharma raised the cash from Invesco and Woodford Investment, and issued an equity stake to Novartis.
Baxter, Takeda, Shire and Lundbeck will all exit central nervous system disorder drug developer Naurex, which had raised $160m in funding.
Celgene will invest $17m in the immuno-oncology company, also backed by Sorrento, as it floats in the largest biotech initial public offering ever.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
